FIELD: medicine; pharmaceuticals.
SUBSTANCE: described is a pharmaceutical composition for use in treating atopic dermatitis. Pharmaceutical composition contains digomogamma-linolenic acid (DGLA) or alkyl ether DGLA, eicosatetraenoic acid, eicosatrienoic acid, oleic acid, linoleic acid and eicosandienoic acid encapsulated in a capsular shell. DGLA or DGLA alkyl ester is at least 95 % by weight of the total amount of fatty acids in the pharmaceutical composition. Said pharmaceutical composition is delivered orally. Encapsulated shell is encapsulated from 200 mg to 1 g of DGLA or alkyl ether of DGLA. Pharmaceutical composition is administered in amount of 1 to 8 capsules a day. Capsule shell contains gelatine and glycerin. Atopic dermatitis is a severe atopic dermatitis.
EFFECT: oral administration of the pharmaceutical composition according to the invention provides treating atopic dermatitis.
11 cl, 23 dwg, 24 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RAPID REDUCTION OF MOTOR FLUCTUATIONS ACCOMPANYING PARKINSON'S DISEASE | 2014 |
|
RU2698330C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| COMPOSITIONS CONTAINING 15-HEPE, AND METHODS OF USING THEM | 2016 |
|
RU2737089C2 |
| METHODS OF TREATING SJOGREN SYNDROME USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2824354C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| METHODS FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS | 2017 |
|
RU2766577C2 |
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND METHODS OF USING THEM | 2015 |
|
RU2731000C2 |
| IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | 2020 |
|
RU2822089C2 |
| ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
